PTCT logo

PTCT
PTC Therapeutics Inc

4,290
Mkt Cap
$5.55B
Volume
659,288.00
52W High
$87.50
52W Low
$35.95
PE Ratio
8.66
PTCT Fundamentals
Price
$67.00
Prev Close
$66.75
Open
$65.85
50D MA
$70.10
Beta
1.20
Avg. Volume
1.17M
EPS (Annual)
$7.78
P/B
-26.59
Rev/Employee
$1.75M
$5,161.47
Loading...
Loading...
News
all
press releases
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors PR Newswire WARREN...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
SG Americas Securities LLC Has $67.94 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT
SG Americas Securities LLC boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 587.5% in the fourth quarter, according to the company in its most recent Form 13F...
MarketBeat·2d ago
News Placeholder
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Analysts
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has received an average recommendation of "Moderate Buy" from the fifteen research firms that are covering the firm, MarketBeat reports. One...
MarketBeat·3d ago
News Placeholder
JPMorgan Chase & Co. Trims Stock Position in PTC Therapeutics, Inc. $PTCT
JPMorgan Chase & Co. cut its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 18.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 490,934 shares of the biopharmaceutical company's stock after s...
MarketBeat·4d ago
News Placeholder
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
Zacks·10d ago
News Placeholder
KROS: Is the Discount Book Value a Value Trap?
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
Zacks·10d ago
News Placeholder
KROS Stock: What to Know About Rinvatercept in DMD
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.
Zacks·10d ago
News Placeholder
Boxer Capital Management LLC Invests $12.27 Million in PTC Therapeutics, Inc. $PTCT
Boxer Capital Management LLC purchased a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities...
MarketBeat·12d ago
News Placeholder
Matthew Klein Sells 2,662 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Matthew Klein sold 2,662 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average...
MarketBeat·13d ago
News Placeholder
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire WARREN, N.J., March 13...
PR Newswire·13d ago
<
1
2
...
>

Latest PTCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.